AKBA — Akebia Therapeutics Income Statement
0.000.00%
- $213.79m
- $201.97m
- $194.62m
- 32
- 51
- 65
- 47
Annual income statement for Akebia Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | R2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K/A | 10-K/A | 10-K/A | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 335 | 295 | 212 | 292 | 195 |
Cost of Revenue | |||||
Gross Profit | 223 | 162 | 109 | 270 | 155 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 621 | 672 | 476 | 374 | 241 |
Operating Profit | -286 | -378 | -265 | -81.7 | -46.8 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -286 | -385 | -282 | -94.2 | -51.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -280 | -385 | -282 | -94.2 | -51.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -280 | -385 | -282 | -94.2 | -51.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -280 | -385 | -282 | -94.2 | -51.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.36 | -1.8 | -1.61 | -0.258 | -0.265 |